Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · IEX Real-Time Price · USD
2.580
-0.060 (-2.27%)
Apr 17, 2024, 4:00 PM EDT - Market closed
-2.27%
Market Cap 211.89M
Revenue (ttm) 26.77M
Net Income (ttm) -22.06M
Shares Out 82.13M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 228,117
Open 2.650
Previous Close 2.640
Day's Range 2.580 - 2.710
52-Week Range 1.330 - 3.290
Beta 1.34
Analysts Strong Buy
Price Target 4.50 (+74.42%)
Earnings Date May 7, 2024

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 122
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 74.42% from the latest price.

Price Target
$4.5
(74.42% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulato...

6 weeks ago - GlobeNewsWire

Stereotaxis Reports 2023 Full Year Financial Results

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

6 weeks ago - GlobeNewsWire

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

ST. LOUIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients ...

7 weeks ago - GlobeNewsWire

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

2 months ago - GlobeNewsWire

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have bee...

3 months ago - GlobeNewsWire

Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients

LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington,...

5 months ago - GlobeNewsWire

Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference

ST. LOUIS, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

5 months ago - GlobeNewsWire

Stereotaxis Reports 2023 Third Quarter Financial Results

ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

5 months ago - GlobeNewsWire

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pati...

6 months ago - GlobeNewsWire

Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023

ST. LOUIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

6 months ago - GlobeNewsWire

Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will p...

7 months ago - GlobeNewsWire

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

ST. LOUIS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicia...

8 months ago - GlobeNewsWire

Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment

ST. LOUIS, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

8 months ago - GlobeNewsWire

Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium

ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its techn...

8 months ago - GlobeNewsWire

Stereotaxis Reports 2023 Second Quarter Financial Results

ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

8 months ago - GlobeNewsWire

Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients

ST. LOUIS, July 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pati...

9 months ago - GlobeNewsWire

Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023

ST. LOUIS, July 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

9 months ago - GlobeNewsWire

Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter

ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intend...

10 months ago - GlobeNewsWire

Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference

ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fisc...

11 months ago - GlobeNewsWire

Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology

ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patient...

11 months ago - GlobeNewsWire

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott's EnSite™ X EP System with Stereotaxis' Robotic ...

11 months ago - GlobeNewsWire

Stereotaxis Reports 2023 First Quarter Financial Results

ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

1 year ago - GlobeNewsWire

Stereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023

ST. LOUIS, April 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...

1 year ago - GlobeNewsWire

Over 1,000 Cardiac Patients Treated with Genesis Robotic System

ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,0...

1 year ago - GlobeNewsWire

Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening...

1 year ago - GlobeNewsWire